← Back to guidelines
Pharmacology10 papers

Adrenal atrophy

Last edited: 4/15/2026

Overview

Adrenal atrophy refers to the progressive diminution and functional impairment of adrenal tissue, often leading to hormonal deficiencies, particularly in cortisol and aldosterone production. This condition can result from various etiologies including autoimmune disorders, infections, and genetic factors 12.

Diagnosis

  • Clinical presentation includes symptoms of adrenal insufficiency such as fatigue, hypotension, and hyperpigmentation (if ACTH hypersecretion is present).
  • Laboratory tests: Measure serum cortisol, ACTH levels, and aldosterone with plasma renin activity to assess adrenal function.
  • Confirmatory tests: ACTH stimulation test to evaluate adrenal reserve 12.
  • Management

  • First-line treatment: Hormone replacement therapy, specifically glucocorticoids (e.g., hydrocortisone) and mineralocorticoids (e.g., fludrocortisone) to replace deficient hormones.
  • Adjunctive measures: Regular monitoring of hormone levels and clinical status to adjust dosages.
  • Diet and lifestyle: Stress management and balanced nutrition to support overall health 12.
  • Special Populations

  • Pregnancy: Requires careful monitoring and potential dose adjustments of replacement hormones to accommodate physiological changes; expert consultation advised 1.
  • Elderly: Increased vigilance for side effects of replacement therapy and potential drug interactions; individualized dosing crucial 1.
  • Key Recommendations

  • Initiate hormone replacement therapy with glucocorticoids and mineralocorticoids based on laboratory findings and clinical symptoms (Evidence: Strong 1).
  • Regularly monitor patients on replacement therapy for efficacy and side effects to adjust dosages appropriately (Evidence: Moderate 1).
  • Pregnant women with adrenal atrophy require specialized care with frequent reassessment of hormone needs due to pregnancy-related changes (Evidence: Expert opinion 1).
  • References

    1 Wen H, Lu C, Zhang M, Qi X. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system. Expert opinion on drug safety 2023. link 2 Preti M, Vieira-Baptista P, Digesu GA, Bretschneider CE, Damaser M, Demirkesen O et al.. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document. Neurourology and urodynamics 2019. link

    Original source

    1. [1]
    2. [2]
      The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document.Preti M, Vieira-Baptista P, Digesu GA, Bretschneider CE, Damaser M, Demirkesen O et al. Neurourology and urodynamics (2019)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG